Pol γA and Pol γB purification was carried out following the previously published protocol (57 (link)). Briefly, PolγB ΔI4 variant was expressed in E. coli BL21-RIL and purified using Ni-NTA agarose (Qiagen) and Mono S affinity chromatography. Pol γA was expressed in Sf9 cells and purified on TALON (Clontech) and Superdex200 size exclusion columns. Purified Pol γA was mixed with Pol γB at a 1:2 M ratio and applied to the Superdex200 gel filtration column. Peak fractions corresponding to the Pol γAB holoenzyme heterotrimer were pooled and concentrated. Purity was judged to be ∼98% using SDS-PAGE. PARP-1 was expressed in E. coli BL21 (DE3) and purified per a published protocol (58 (link)). Following cell lysis, PARP-1 was purified by sequential application to Ni-NTA agarose (Qiagen), HiTrap Heparin HP column (GE Healthcare), and Superdex200 chromatography columns. Human Poly(ADP-ribose) glycohydrolase catalytic domain (deletion of N-terminal 455 amino acids) (hPARG-ΔN455) was purified according to Tucker et al. (59 ). After expression in E. coli BL21 (DE3), hPARG-ΔN455 was purified by sequential application to Ni-NTA agarose (Qiagen) and Superdex200 chromatography columns.
Free full text: Click here